🔎 Trials Near Me

Почетна › Мијелофиброза › Kanzas

Kliničke studije za Мијелофиброза u državi Kanzas

8 studija za Мијелофиброза traži učesnike na lokacijama u državi Kanzas.

Gradovi u državi Kanzas

Zvanični tekst studije (na engleskom)

A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

  • University of Kansas Medical Center, Kansas City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06343805

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

  • University of Kansas Clinical Research Center, Fairway
  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Hospital-Indian Creek Campus, Overland Park
  • и још 1
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06661915

A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms

  • Site US21, Kansas City
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT07849231

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

  • The University of Kansas Cancer Center-Westwood, Westwood
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT07447817

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

  • The University of Kansas Cancer Center, Fairway
Тражи се учесникРана фаза 1Здраве особе су добродошле
Узраст 18 и старији · Оба пола · Ажурирано 6. 5. 2026. · NCT06414681

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

  • The University of Kansas Cancer Center, Westwood
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 17. 4. 2026. · NCT06034002

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

  • University of Kansas Medical Center, Westwood
Тражи се учесникФаза 2
Узраст од 18 до 66 · Оба пола · Ажурирано 17. 3. 2026. · NCT06859424

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  • University of Kansas Cancer Center - Westwood, Westwood
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2025. · NCT06479135

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.